Recruiting

NCT Number: NCT07836621

Pyeloplasty in Pediatric Patients With Differential Renal Function Less Than 10%

This study aims to evaluate the postoperative outcomes of pyeloplasty in pediatric patients presenting with ureteropelvic junction obstruction and preoperative differential renal function less than 10%, focusing on:

* Improvement or stabilization of renal function after surgery. * Radiological improvement in hydronephrosis. * Clinical outcomes such as symptom relief and complication rates.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Pyeloplasty Differential Renal Function Pediatric Patients

Age range

1 month–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Tanta University

Tanta, El-Gharbia, 31527, Egypt

Location status: Recruiting

Location contact

Mohamed A Omer, MD

SUB_INVESTIGATOR

Mohamed El Maadawy, MD

SUB_INVESTIGATOR

Salah Nagla, MD

SUB_INVESTIGATOR

Yossof H Abdul-Qader, MBBCH

CONTACT

[email protected]

00201005669720

About this study

Ureteropelvic junction obstruction (UPJO) represents one of the most common causes of hydronephrosis in children.

Historically, kidneys with differential renal function (DRF) below 10% were considered non-salvageable, and nephrectomy was often recommended.

However, recent evidence suggests that pediatric renal units retain significant potential for recovery even when preoperative function is severely reduced.

Numerous studies over the past decade have demonstrated that pyeloplasty in low-functioning kidneys can result in functional improvement, stabilization, and significant symptomatic relief.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age from 1 month to 18 years.
Diagnosis of primary ureteropelvic junction obstruction.
Preoperative differential renal function <10% on MAG3 renogram.
A normal contralateral kidney.

Exclusion criteria

Secondary Ureteropelvic Junction Obstruction (UPJO) (postoperative, traumatic, or secondary to other anomalies).
Solitary functioning kidney.
Associated vesicoureteral reflux or posterior urethral valves.
Severe comorbidities affecting renal function.
Incomplete medical records.

Treatment and study plan

Pyeloplasty

Procedure

Patients will undergo Anderson-Hynes dismembered pyeloplasty for primary ureteropelvic junction obstruction. The procedure was performed through an open, laparoscopic, or mini-incision approach according to the patient's age and the surgeon's clinical judgment. A ureteral stent was inserted when indicated.

Primary outcomes

Change in Differential Renal Function After Pyeloplasty

Time frame: 6 months after pyeloplasty

Differential renal function of the affected kidney will be assessed using MAG-3 diuretic renography. Renal function will be classified as improved when differential renal function increases by at least 5 percentage points, stable when the change is less than 5 percentage points in either direction, and deteriorated when it decreases by at least 5 percentage points.

Study contacts

Contact information is provided by the study sponsor or research team.

Yossof H Abdul-Qader, MBBCH

CONTACT

[email protected]

00201005669720

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Official study title

Outcomes of Pyeloplasty in Pediatric Patients With Differential Renal Function Less Than 10%

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2027
First posted: Sep 23, 2026
Registry last updated: Sep 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, not recruiting